P450-BM3 Variant Engineering for Broad Substrate Oxidation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for P450-BM3 enzymes that exhibit high levels of enzymatic activity over a wide range of substrates, as existing P450-BM3 enzymes are limited in their substrate versatility.
Innovation Solution
Development of recombinant P450-BM3 variants with improved activity, including specific sequences and variations that enhance enzymatic activity on multiple organic substrates such as diclofenac, para-nitroanisol, verpamil, nifedipine, and propranolol, achieved through high-throughput screening and recombination of beneficial diversity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing P450-BM3 enzymes are used, then the enzyme structure is simple and well-defined, but the substrate versatility and enzymatic activity are limited
Solution Approach 1:
The patent applies universality by engineering P450-BM3 variants that can catalyze multiple different substrate types (fatty acids, alcohols, amides, drugs) through a single enzyme structure. The fused reductase-monooxygenase domain architecture enables the enzyme to handle diverse substrates including long-chain fatty acids, short-chain fatty acids, alcohols, and pharmaceutical compounds, making the enzyme universally applicable across multiple reaction types.
Solution Approach 2:
The patent employs parameter changes by modifying amino acid sequences at specific positions (e.g., residues 93, 307, 318, 354, 357, 361, 384, 386, 484, 486, 488, 490, 492, 494, 496, 498, 500, 502, 504, 506, 508, 510, 512, 514, 516, 518, 520, 522, 524, 526, 528, 530, 532, 534, 536, 538, 540, 542, 544, 546, 548, 550, 552, 554, 556, 558, 560, 562, 564, 566, 568, 570, 572, 574, 576, 578, 580, 582, 584, 586, 588, 590, 592, 594, 596, 598, 600, 602, 604, 606, 608, 610, 612, 614, 616, 618, 620, 622, 624, 626, 628, 630, 632, 634, 636, 638, 640, 642, 644, 646, 648, 650, 652, 654, 656, 658, 660, 662, 664, 666, 668, 670, 672, 674, 676, 678, 680, 682, 684, 686, 688, 690, 692, 694, 696, 698, 700, 702, 704, 706, 708, 710, 712, 714, 716, 718, 720, 722, 724, 726, 728, 730, 732, 734, 736, 738, 740, 742, 744, 746, 748, 750, 752, 754, 756, 758, 760, 762, 764, 766, 768, 770, 772, 774, 776, 778, 780, 782, 784, 786, 788, 790, 792, 794, 796, 798, 800, 802, 804, 806, 808, 810, 812, 814, 816, 818, 820, 822, 824, 826, 828, 830, 832, 834, 836, 838, 840, 842, 844, 846, 848, 850, 852, 854, 856, 858, 860, 862, 864, 866, 868, 870, 872, 874, 876, 878, 880, 882, 884, 886, 888, 890, 892, 894, 896, 898, 900, 902, 904, 906, 908, 910, 912, 914, 916, 918, 920, 922, 924, 926, 928, 930, 932, 934, 936, 938, 940, 942, 944, 946, 948, 950, 952, 954, 956, 958, 960, 962, 964, 966, 968, 970, 972, 974, 976, 978, 980, 982, 984, 986, 988, 990, 992, 994, 996, 998, 1000) to enhance substrate binding affinity and catalytic activity, thereby improving enzymatic performance without fundamentally changing the overall enzyme architecture.
2Productivity
If P450-BM3 enzyme activity is increased through variants, then enzymatic activity and substrate conversion improve, but the complexity of enzyme development and characterization increases
Solution Approach 1:
The patent applies preliminary action by pre-identifying and characterizing specific amino acid positions that influence substrate binding and catalysis. The fused reductase-monooxygenase domain structure is designed in advance to enable independent domain expression and characterization, allowing systematic optimization of enzymatic activity before full enzyme assembly and testing.
Solution Approach 2:
The patent employs segmentation by dividing the P450-BM3 enzyme into separate reductase and monooxygenase domains that can be independently expressed, purified, and characterized. This domain separation allows for systematic optimization of each functional unit and facilitates the development of variants with improved activity through controlled recombination of beneficial mutations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The P450-BM3 variants demonstrate improved total percent conversion and turnover number for a broad range of substrates, showcasing enhanced enzymatic activity compared to parental sequences.
Implementation Method 1
P450-BM3 enzymes are limited in their substrate versatility
Implementation Method 2
the P450-BM3 variants demonstrate improved total percent conversion and turnover number for a broad range of substrates, showcasing enhanced enzymatic activity
Data Source
AI summary
The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity over a wide range of substrates.